Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.

Nicole MaphisShanya JiangGuixiang XuOlga N Kokiko-CochranSaktimayee M RoyLinda J Van EldikD Martin WattersonBruce T LambKiran Bhaskar

Published in: Alzheimer's research & therapy (2016)

Taken together, these studies support p38α MAPK as a valid therapeutic target for the treatment of tauopathies.

Keyphrases